Company / Accounts Receivable
Ernexa Therapeutics Inc. Accounts Receivable History
FY2014-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$116.0K
FY2020
5-year range
$116.0K / $1.2M
FY2016-FY2020
Trend
-90.3%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 7 years, ranging from $116,000 in FY2020 to $2M in FY2014.
Based on SEC 10-K filings.
$116,000 in FY2020 with a 5-year CAGR of -33.9%.
Declined from $1M to $116,000 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -45.4%
- 5-Year CAGR
- -33.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -33.9%, indicating a declining trend.
- In FY2020, accounts receivable decreased 90.3% year-over-year.
- Peak accounts receivable was recorded in FY2014.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2020 | $116.0K | -90.3% |
| FY2019 | $1.2M | +4.5% |
| FY2018 | $1.1M | +60.1% |
| FY2017 | $714.0K | -23.1% |
| FY2016 | $928.0K | +1.0% |
| FY2015 | $919.0K | -58.0% |
| FY2014 | $2.2M | +241.7% |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026